Optimizing HER3-Targeted Therapy for NSCLC: Strategies for Early Detection and Management of Adverse Events

Optimizing HER3-Targeted Therapy for NSCLC: Strategies for Early Detection and Management of Adverse Events

In this textbased activity a leading expert discusses how to optimize HER3targeted therapy for patients with NSCLC with a focus on how to identify and mitigate HER3targeted therapyrelated adverse events

  • Provider:Clinical Care Options
  • Activity Link: https://clinicaloptions.com/CE-CME/oncology/nsclc-her3-ae-management-1/26497-64031
  • Start Date: 2024-12-05 06:00:00
  • End Date: 2024-12-05 06:00:00
  • Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
  • Commercial Support: Source: Daiichi Sankyo, Inc. - Amount: 65140.0 - Is Kind Support: False
  • Activity Type: Enduring Material
  • CME Finder Type: Online Learning
  • Fee to Participate: No, it's free
  • Measured Outcome: Learner Knowledge, Learner/Team Competence
  • Provider Ship: Directly Provided
  • Registration: Open to all
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.